*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ Bayer/NNP AG/NNP ]
said/VBD 
[ it/PRP ]
plans/VBZ to/TO 
[ more/RBR ]
than/IN 
[ triple/VB its/PRP$ investment/NN ]
in/IN 
[ research/NN ]
and/CC 
[ development/NN ]
in/IN 
[ biotechnology/NN ]
and/CC 
[ genetic/JJ engineering/NN ]
within/IN 
[ the/DT next/JJ five/CD years/NNS ]
,/, but/CC 
[ the/DT company/NN ]
cautioned/VBD that/IN 
[ it/PRP ]
is/VBZ n't/RB expecting/VBG 
[ a/DT quick/JJ payoff/NN ]
./. 

======================================

``/`` 
[ Genetic/JJ technology/NN ]
is/VBZ n't/RB 
[ a/DT way/NN ]
to/TO make/VB 
[ money/NN ]
quickly/RB ,/, ''/'' said/VBD 
[ Karl/NNP Heinz/NNP Buechel/NNP ]
,/, 
[ head/NN ]
of/IN 
[ research/NN ]
at/IN 
[ Bayer/NNP ]
./. 

``/`` 
[ We/PRP ]
expect/VBP 
[ our/PRP$ ]
 {/( 
[ revenue/NN ]
 }/) and/CC 
[ earnings/NNS ]
in/IN 
[ that/DT sector/NN ]
to/TO develop/VB slowly/RB ./. 

''/'' 
======================================

As/IN 
[ West/NNP Germany/NNP 's/POS third-largest/JJ chemical/NN ]
and/CC 
[ pharmaceutical/JJ company/NN ]
after/IN 
[ BASF/NNP AG/NNP ]
and/CC 
[ Hoechst/NNP AG/NNP ]
,/, 
[ Bayer/NNP ]
is/VBZ fearful/JJ of/IN falling/VBG behind/RB in/IN 
[ the/DT accelerating/VBG race/NN ]
for/IN 
[ new/JJ products/NNS ]
in/IN 
[ medicine/NN ]
and/CC 
[ agriculture/NN ]
./. 

======================================

Consequently/RB ,/, 
[ it/PRP ]
plans/VBZ to/TO increase/VB 
[ its/PRP$ annual/JJ research/NN ]
and/CC 
[ development/NN budget/NN ]
in/IN 
[ biotechnology/NN ]
and/CC 
[ genetic/JJ engineering/NN ]
to/TO 
[ $/$ 265.1/CD million/CD ]
in/IN 
[ the/DT next/JJ five/CD years/NNS ]
from/IN about/RB 
[ $/$ 79.5/CD million/CD this/DT year/NN ]
./. 

======================================

``/`` 
[ Genetic/JJ technology/NN ]
is/VBZ unavoidable/JJ for/IN 
[ us/PRP ]
out/IN of/IN 
[ pure/JJ economic/JJ reasons/NNS ]
,/, ''/'' 
[ Bayer/NNP Chairman/NNP Hermann/NNP Strenger/NNP ]
said/VBD at/IN 
[ a/DT special/JJ forum/NN ]
on/IN 
[ biotechnology/NN ]
earlier/RBR 
[ this/DT month/NN ]
./. 

``/`` 
[ We/PRP ]
must/MD develop/VB 
[ new/JJ technologies/NNS ]
if/IN 
[ we/PRP ]
are/VBP to/TO grow/VB and/CC remain/VB 
[ competitive/JJ ]
./. 

''/'' 
======================================

[ Bayer/NNP ]
also/RB will/MD double/VB 
[ the/DT capacity/NN ]
of/IN 
[ its/PRP$ research/NN center/NN ]
in/IN 
[ West/NNP Haven/NNP ]
,/, 
[ Conn./NNP ]
,/, investing/VBG about/RB 
[ $/$ 50/CD million/CD ]
by/IN 
[ the/DT end/NN ]
of/IN 
[ 1991/CD ]
and/CC turning/VBG 
[ it/PRP ]
into/IN 
[ one/CD ]
of/IN 
[ the/DT world/NN 's/POS largest/JJS such/JJ facilites/NNS ]
,/, 
[ Mr./NNP Strenger/NNP ]
said/VBD ./. 

======================================

[ Analysts/NNS ]
were/VBD encouraged/VBN by/IN 
[ Bayer/NNP 's/POS announcement/NN ]
./. 

``/`` When/WRB 
[ a/DT company/NN ]
of/IN 
[ that/DT size/NN ]
and/CC 
[ brainpower/NN ]
invests/VBZ heavily/RB into/IN 
[ research/NN ]
,/, 
[ that/WDT ]
always/RB spells/VBZ 
[ good/JJ news/NN ]
for/IN 
[ the/DT company/NN ]
,/, ''/'' said/VBD 
[ Kiran/NNP Bhojani/NNP ]
,/, 
[ who/WP ]
follows/VBZ 
[ chemicals/NNS ]
and/CC 
[ pharmaceuticals/NNS stocks/NNS ]
for/IN 
[ Shroeder/NNP ]
,/, 
[ Muenchmeyer/NNP ]
,/, 
[ Hengst/NNP Investment/NNP G.m.b/NNP ]
./. 

[ H./NNP ]
in/IN 
[ Frankfurt/NNP ]
./. 

``/`` 
[ I/PRP ]
think/VBP 
[ this/DT strategy/NN ]
should/MD work/VB real/RB well/RB for/IN 
[ Bayer/NNP ]
,/, 
[ which/WDT ]
is/VBZ focused/VBN heavily/RB on/IN 
[ new/JJ pharmaceutical/JJ products/NNS ]
./. 

''/'' 
======================================

[ Company/NN executives/NNS stress/VBP Bayer/NN  ]
is/VBZ prepared/VBN to/TO wait/VB for/IN 
[ a/DT payoff/NN ]
on/IN 
[ its/PRP$ investment/NN ]
for/IN at/IN 
[ least/JJS 10/CD years/NNS ]
./. 

According/VBG to/TO 
[ a/DT study/NN ]
done/VBN by/IN 
[ the/DT IFO/NNP research/NN institute/NN ]
in/IN 
[ Munich/NNP ]
,/, 
[ the/DT market/NN ]
world-wide/RB for/IN genetically/RB engineered/VBN 
[ products/NNS ]
is/VBZ expected/VBN to/TO soar/VB tenfold/RB to/TO about/RB 
[ $/$ 5.8/CD billion/CD ]
by/IN 
[ 1995/CD ]
./. 

[ Companies/NNS ]
using/VBG 
[ genetic/JJ technology/NN ]
will/MD see/VB 
[ sales/NNS ]
gaining/VBG 
[ 10/CD %/NN ]
to/TO 
[ 20/CD %/NN ]

[ a/DT year/NN ]
,/, 
[ the/DT IFO/NNP study/NN ]
said/VBD ./. 

======================================

Meanwhile/RB ,/, 
[ Bayer/NNP 's/POS world-wide/JJ sales/NNS ]
of/IN 
[ biotechnology/NN products/NNS ]
are/VBP expected/VBN to/TO rise/VB between/IN 
[ 5/CD %/NN ]
and/CC 
[ 7/CD %/NN ]

[ this/DT year/NN ]
from/IN more/JJR than/IN 
[ $/$ 1.3/CD billion/CD ]
in/IN 
[ 1988/CD ]
,/, 
[ Mr./NNP Buechel/NNP ]
said/VBD ./. 

But/CC 
[ growth/NN ]
will/MD slow/VB in/IN 
[ the/DT next/JJ few/JJ years/NNS ]
until/IN 
[ new/JJ products/NNS ]
come/VBD on/IN 
[ the/DT market/NN ]
,/, 
[ Mr./NNP Buechel/NNP ]
predicted/VBD ./. 

======================================

[ Bayer/NNP ]
is/VBZ focusing/VBG on/IN 
[ the/DT most/JJS pressing/JJ ]
of/IN 
[ the/DT world/NN 's/POS health/NN problems/NNS ]
,/, targeting/VBG 
[ such/JJ ailments/NNS ]
as/IN 
[ diabetes/NN ]
,/, 
[ Alzheimer/NNP 's/POS disease/NN ]
,/, acquired/JJ 
[ immune/JJ deficiency/NN syndrome/NN ]
and/CC 
[ the/DT common/JJ cold/NN ]
./. 

[ It/PRP ]
also/RB aims/VBZ at/IN developing/VBG 
[ diagnostic/JJ tools/NNS ]
for/IN 
[ early/JJ detection/NN ]
of/IN 
[ cancer/NN ]
,/, 
[ arteriosclerosis/NN ]
and/CC 
[ diabetes/NN ]
,/, and/CC has/VBZ intensified/VBN 
[ research/NN ]
into/IN 
[ application/NN ]
of/IN genetically/RB engineered/VBN 
[ products/NNS ]
in/IN 
[ agriculture/NN ]
./. 

======================================

[ The/DT company/NN ]
does/VBZ n't/RB have/VB as/RB yet/RB 
[ any/DT ]
genetically/RB engineered/VBN 
[ drugs/NNS ]
on/IN 
[ the/DT market/NN ]
,/, although/IN 
[ it/PRP ]
is/VBZ about/RB to/TO apply/VB to/TO 
[ the/DT U.S./NNP Food/NNP ]
and/CC 
[ Drug/NNP Administration/NNP ]
for/IN 
[ permission/NN ]
to/TO sell/VB 
[ Factor-VIII/NNP ]
,/, 
[ a/DT blood-clotting/JJ agent/NN ]
developed/VBN by/IN 
[ Genentech/NNP Corp./NNP ]
and/CC licensed/VBN to/TO 
[ Miles/NNP Inc./NNP ]
,/, 
[ Bayer/NNP 's/POS U.S./NNP subsidiary/NN ]
,/, for/IN 
[ commercial/JJ production/NN ]
./. 

[ Clinical/JJ trials/NNS ]
have/VBP shown/VBN 
[ the/DT agent/NN ]
to/TO be/VB 
[ effective/JJ ]
against/IN 
[ hemophilia/NN ]
./. 

======================================

[ Mr./NNP Buechel/NNP ]
said/VBD 
[ Bayer/NNP ]
will/MD apply/VB to/TO 
[ Japanese/JJ authorities/NNS ]
for/IN 
[ permission/NN ]
to/TO 
[ market/VB Factor/NNP VIII/NNP ]
there/RB sometime/RB 
[ next/JJ year/NN ]
./. 

[ Preliminary/JJ reports/NNS ]
from/IN 
[ the/DT Japanese/JJ medical/JJ community/NN ]
are/VBP ``/`` highly/RB 
[ complimentary/JJ ]
,/, ''/'' 
[ he/PRP ]
said/VBD ./. 

[ Application/NN ]
to/TO 
[ West/JJ German/JJ ]
and/CC 
[ other/JJ European/JJ authorities/NNS ]
is/VBZ also/RB being/VBG considered/VBN ./. 

======================================

[ Horst/NNP Meyer/NNP ]
,/, 
[ head/NN ]
of/IN 
[ pharmaceutical/JJ research/NN ]
at/IN 
[ Bayer/NNP ]
,/, said/VBD that/IN in/IN 
[ the/DT next/JJ two/CD years/NNS ]
more/RBR genetically/RB engineered/VBN 
[ products/NNS ]
are/VBP expected/VBN to/TO be/VB market-ready/JJ ./. 

[ One/CD ]
is/VBZ Acarbose/NNP ,/, 
[ an/DT anti-diabetes/JJ drug/NN ]
,/, 
[ the/DT other/JJ ]
is/VBZ 
[ Dresylon/NNP ]
,/, to/TO be/VB used/VBN in/IN 
[ intensive-care/NN therapy/NN ]
./. 

======================================

At/IN 
[ earlier/JJR stages/NNS ]
of/IN 
[ development/NN ]
are/VBP 
[ attempts/NNS ]
to/TO produce/VB genetically/RB engineered/VBN 
[ anti-shock/JJ agents/NNS Aprotinine/NNP ]
and/CC 
[ tumor/NN necrosis/NN factor/NN antibodies/NNS ]
,/, as/RB well/RB as/IN to/TO 
[ clone/VB rhinovirus-receptors/NNS ]
as/IN 
[ a/DT drug/NN ]
against/IN 
[ the/DT common/JJ cold/NN ]
,/, 
[ Mr./NNP Meyer/NNP ]
said/VBD ./. 

======================================

[ Bayer/NNP ]
is/VBZ also/RB developing/VBG genetically/RB improved/VBN 
[ plants/NNS ]
,/, looking/VBG for/IN 
[ ways/NNS ]
to/TO raise/VB 
[ their/PRP$ resistance/NN ]
to/TO 
[ herbicides/NNS ]
and/CC studying/VBG 
[ general/JJ plant/NN defense/NN mechanisms/NNS ]
./. 

[ No/DT marketable/JJ products/NNS ]
however/RB ,/, are/VBP as/RB yet/RB available/JJ ./. 

======================================

[ Mr./NNP Buechel/NNP ]
stressed/VBD that/IN while/IN expanding/VBG 
[ its/PRP$ research/NN capacity/NN ]
in/IN 
[ the/DT U.S./NNP ]
and/CC later/RB building/VBG 
[ a/DT research/NN ]
and/CC 
[ development/NN center/NN ]
in/IN 
[ Japan/NNP ]
,/, 
[ Bayer/NNP ]
will/MD keep/VB 
[ the/DT research/NN ]
going/VBG 
[ strong/JJ ]
in/IN 
[ West/NNP Germany/NNP ]
./. 

[ BASF/NNP AG/NNP ]
got/VBD 
[ a/DT jump/NN ]
on/IN 
[ Bayer/NNP ]
when/WRB 
[ it/PRP ]
announced/VBD 
[ last/JJ year/NN ]

[ it/PRP ]
was/VBD setting/VBG up/RP 
[ a/DT large/JJ research/NN ]
and/CC 
[ development/NN facility/NN ]
near/IN 
[ Boston/NNP ]
./. 

======================================

[ Both/CC Bayer/NNP ]
and/CC 
[ BASF/NNP ]
claim/VBP that/IN 
[ West-German/JJ government/NN support/NN ]
for/IN 
[ development/NN ]
of/IN 
[ genetic/JJ technology/NN ]
is/VBZ far/RB below/IN 
[ that/DT ]
in/IN 
[ the/DT U.S/NNP ]
./. 

======================================

In/IN 
[ 1987/CD ]
,/, 
[ the/DT West/JJ German/JJ support/NN ]
for/IN 
[ biotechnology/NN ]
and/CC 
[ genetic/JJ engineering/NN ]
totaled/VBD 
[ $/$ 115/CD million/CD ]
,/, while/IN 
[ the/DT industry/NN ]
invested/VBD nearly/RB 
[ $/$ 500/CD million/CD ]
./. 

[ That/DT ]
compares/VBZ with/IN 
[ $/$ 2.7/CD billion/CD ]
spent/VBN by/IN 
[ the/DT U.S./NNP government/NN ]
in/IN 
[ the/DT same/JJ year/NN ]
on/IN 
[ direct/JJ ]
and/CC 
[ indirect/JJ ]
funding/NN of/IN 
[ research/NN ]
and/CC 
[ development/NN ]
in/IN 
[ that/DT field/NN ]
,/, while/IN 
[ the/DT U.S./NNP industry/NN ]
spent/VBD 
[ an/DT additional/JJ $/$ 2/CD billion/CD ]
./. 
